Browse > Article
http://dx.doi.org/10.4014/jmb.1901.01061

Arctigenin Inhibits Etoposide Resistance in HT-29 Colon Cancer Cells during Microenvironmental Stress  

Yoon, Sae-Bom (Department of Food Science and Biotechnology, Kyungnam University)
Park, Hae-Ryong (Department of Food Science and Biotechnology, Kyungnam University)
Publication Information
Journal of Microbiology and Biotechnology / v.29, no.4, 2019 , pp. 571-576 More about this Journal
Abstract
Microenvironmental stress, which is naturally observed in solid tumors, has been implicated in anticancer drug resistance. This tumor-specific stress causes the degradation of topoisomerase $II{\alpha}$, rendering cells resistant to topoisomerase $II{\alpha}$-targeted anticancer agents. In addition, microenvironmental stress can induce the overexpression of 78kDa glucose regulated protein (GRP78), which can subsequently block the activation of apoptosis induced by treatment with anticancer agents. Therefore, inhibition of topoisomerase $II{\alpha}$ degradation and reduction in GRP78 expression may be effective strategies for inhibiting anticancer drug resistance. In this study, we investigated the active compound arctigenin, which inhibited microenvironmental stress-induced etoposide resistance in HT-29 cells. Arctigenin was also highly toxic to etoposide-resistant HT-29 cells, with an $IC_{50}$ value of $10{\mu}M$ for colony formation. We further showed that arctigenin inhibited the degradation of topoisomerase $II{\alpha}$ and reduced the expression of GRP78. Thus, these results suggest that arctigenin is a novel therapeutic agent that inhibits resistance to etoposide associated with microenvironmental stress conditions.
Keywords
Anticancer resistance; microenvironmental stress; topoisomerase $II{\alpha}$; GRP78; arctigenin;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Goodman GE, Yen YP, Cox TC, Crowley J. 1987. Effect of verapamil on in vitro cytotoxicity of adriamycin and vinblastine in human tumor cells. Cancer Res. 47: 2295-2304.
2 Ahn HJ, Kim JY, Lee CH, Song IS, Liu KH. 2008. Screening of chemosensitizer candidates using natural extracts. J. Life Sci. 9: 1244-1248.
3 Shen DW, Goldenberg S, P astan I, Gottesman MM. 2000. Decreased accumulation of [$^{14}C$] carboplatin in human cisplatin-resistant cells results from reduced energy dependent uptake. J. Cell Physiol. 183: 108-116.   DOI
4 Goto S, Kamada K, Soh Y, Ihara Y, Kondo T. 2002. Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. Jpn. J. Cancer Res. 93: 1047-1056.   DOI
5 Axelson H, Fredlund E, Ovenberger M, Landberg G, Pahlman S. 2005. Hypoxia-induced dedifferentiation of tumor cells-A mechanism behind heterogeneity and aggressiveness of solid tumors. Semin. Cell DevBiol. 16: 554-563.   DOI
6 Brown JM, Giaccia AJ. 1998. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58: 1408-1416.
7 Tomida A, Tsuruo T. 1999. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des. 14: 169-177.
8 Acker T, Plate KH. 2002. A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology. J. Mol. Med. 80: 562-575.   DOI
9 Vaupel P, Yhews O, Hoeckel M. 2001. Treatment resistance of solid tumors: role of hypoxia and anemia. Med. Oncol. 18: 243-259.   DOI
10 Chen AY, Liu LF. 1994. Mechanisms of resistance to topoisomerase inhibitors. Cancer Treat. Res. 73: 263-281.   DOI
11 Coux O, Tanaka, Goldberg AL. 1996. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 65: 801-847.   DOI
12 Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, et al. 1994. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 12: 530-542.   DOI
13 Wang JC. 1996. DNA topoisomerases. Annu. Rev. Biochem. 65: 635-692.   DOI
14 Froelich-Ammon SJ, Osheroff N. 1995. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem. 270: 21429-21432.   DOI
15 Ma Y, Hendershot LM. 2001. The unfolding tale of the unfolded protein pesponse. Cell 107: 827-830.   DOI
16 Mazzarella RA, Green M. 1987. Erp99, and abundant, conserved glycoprotein of the endoplasmic reticulum, is homologous to 90 kDa heat shock protein (hsp90) and the 94 kDa glucose-regulated protein (GRP94). J. Biol. Chem. 262: 74-108.
17 Choo SJ, Park HR, Ryoo IJ, Kim JP, Yun BS, Kim CJ, et al. 2005. Deoxyverrucosidin, a novel GRP78/BiP down-regulator, produced by Penicillium sp. J. Antibiot. 58: 210-213.   DOI
18 Yu JL, Coomber BL, Kerbel RS. 2002. A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation 70: 599-609.   DOI
19 Fernandez PM, Tabbara SO, Jacobs LK, Manning FCR, Tsangaris TN, Schwarts AM, et al. 2000. Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res. Treat. 59: 15-26.   DOI
20 Umehara K, Nakamura M, Miyase T, Kuroyanagi M, Ueno A. 1996. Studies on differentiation inducers. VI. Lignan derivatives from Arctium fructus. (2). Chem. Pharm. Bull. 44: 2300-2304.   DOI
21 Zhao F, Wang L, Liu K. 2009. In vitro anti-inflammatory effects of arctigenin, a lignan from Arctium lappa L., through inhibition on iNOS pathway. J. Ethnopharmacol. 122: 457-462.   DOI
22 Zhang N, Wen Q, Ren L, Liang W, Xia Y, Zhang X, et al. 2013. Neuroprotective effect of arctigenin via upregulation of P-CREB in mouse primary neurons and human SH-SY5Y neuroblastoma cells. Int. J. Mol. 14: 18657-18669.   DOI
23 Ogiso Y, Tomida A, Tsuruo T. 2002. Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumor cells to topoisomerase II-directed drugs. Cancer Res. 62: 5008-5012.
24 Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T. 2000. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res. 60: 2429-2434.